Industry
Marrow raises $173 million to develop sickle cell treatment
Marrow has not said when its planned injectable treatment for sickle cell disease and beta thalassemia will enter clinical testing.

Marrow Therapeutics has emerged from stealth with $173 million in combined Series A and B financing to develop MAR-101 for sickle cell disease and beta thalassemia, BioPharma Dive reported. The company is positioning the treatment as an alternative to gene therapies and gene editing treatments. Those therapies involve modifying a patient’s stem cells in a lab and require chemotherapy conditioning, according to BioPharma Dive.
MAR-101 is a transferrin antibody bioconjugate that links an antibody to small interfering RNA, or siRNA. The treatment is designed to reach a receptor in bone marrow and reactivate cells’ ability to make fetal hemoglobin, BioPharma Dive reported. It would be given by injection and could be administered multiple times if its effects wane. Marrow has not disclosed when it expects MAR-101 to enter clinical testing. The funding, from 11 investors, will also support the company’s manufacturing capabilities.


